<DOC>
	<DOCNO>NCT00220064</DOCNO>
	<brief_summary>The objective study assess efficacy toxicity 2 weekly regimen contain irinotecan combine leucovorin-modified 5-fluorouracil setting relapse refractory upper gastrointestinal tumour . Patients locally advance metastatic adenocarcinoma originate oesophagogastric junction , stomach pancreas previously receive chemotherapy either fail respond relapse initial response eligible treatment study . The response rate , failure-free survival overall survival treat patient two different regime evaluate . Toxicity quality life also monitor closely .</brief_summary>
	<brief_title>A Phase II Trial Evaluating Irinotecan Plus 5FU/LV Patients With Relapsed/Refractory Upper GI Tumours</brief_title>
	<detailed_description />
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically proven adenocarcinoma squamous cell carcinoma Oesophagus , OG junction , stomach pancreas , amenable surgical resection . Bidimensionally measurable disease , unidimensional measurable disease accessible CT scanning , within previously irradiate area . Patients progressive disease previous chemotherapy treatment within three month stop treatment . At least one previous chemotherapy regimen , give least 4 week prior inclusion study . No previous exposure irinotecan . Adequate bone marrow function platelet &gt; 100 X 109/L ; WBC &gt; 3 X 109/L ; Neutrophils &gt; 1.5 X 109/L time study entry . Satisfactory renal function , serum creatinine 135 mol/litre Satisfactory liver function : In absence liver metastasis : Bilirubin &lt; 1.25N ( N=upper limit normal range ) Hepatic transaminases &lt; 2.5N Prothrombin time &lt; 1.5N In presence liver metastasis : Bilirubin &lt; 1.5N Hepatic transaminase &lt; 5N Prothrombin time &lt; 1.5N No uncontrolled medical condition No previous malignant disease except nonmelanotic skin cancer insitu carcinoma uterine cervix . ECOG performance status 0 , 1 2 . Predicted life expectancy &gt; 3 month . Adequate contraceptive precaution Informed write consent Medical psychiatric condition result inability patient give write consent . ECOG Performance status &gt; 2 Intracerebral metastasis meningeal carcinomatosis Unresolved bowel obstruction Uncontrolled angina pectoris , heart failure ( New York heart classification 3 4 ) . Pregnancy/lactation Previous malignancy adequately treat basal cell carcinoma skin cervical carcinoma situ .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>